Loading organizations...
§ Private Profile · Stevenage, Herefordshire, United Kingdom
Clinical-stage biotech developing NT-814, a non-hormonal neurokinin-1,3 receptor antagonist for menopause symptoms.
KaNDy Therapeutics, based in Stevenage, UK, developed non-hormonal treatments for menopause symptoms, primarily focusing on its lead candidate NT-814. The clinical-stage biotech advanced NT-814, a first-in-class oral neurokinin-1,3 receptor antagonist, through successful Phase IIb trials to reduce vasomotor symptoms like hot flashes and improve sleep. The company was acquired by Bayer in September 2020 for an upfront payment of $425 million, with potential for up to an additional $450 million in development milestones and further sales milestones. Prior to its acquisition, KaNDy Therapeutics secured funding from life sciences investors including Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, OrbiMed, and Longitude Capital. KaNDy Therapeutics was founded in 2017 by Mary Kerr and Mike Trower as a spin-off from NeRRe Therapeutics.
KaNDy Therapeutics has raised $32.3M across 1 funding round.
KaNDy Therapeutics has raised $32.3M in total across 1 funding round.
KaNDy Therapeutics has raised $32.3M across 1 funding round. Most recently, it raised $32.3M Series C in August 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 29, 2018 | $32.3M Series C | — | Advent Life Sciences, Forbion, Fountain Healthcare Partners, Josh Richardson, OrbiMed | Announced |
KaNDy Therapeutics has raised $32.3M in total across 1 funding round.
KaNDy Therapeutics's investors include Advent Life Sciences, Forbion, Fountain Healthcare Partners, Josh Richardson, OrbiMed.